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Abstract
Chemokine receptors are G protein-coupled receptors that contain seven transmembrane domains. In particular, CCR2 and
CCR5 and their ligands have been implicated in the pathophysiology of a number of diseases, including rheumatoid arthritis
and multiple sclerosis. Based on their roles in disease, they have been attractive targets for the pharmaceutical industry, and
furthermore, targeting both CCR2 and CCR5 can be a useful strategy. Owing to the importance of these receptors,
information regarding the binding site is of prime importance. Structural studies have been hampered due to the lack of X-
ray crystal structures, and templates with close homologs for comparative modeling. Most of the previous models were
based on the bovine rhodopsin and b2-adrenergic receptor. In this study, based on a closer homolog with higher resolution
(CXCR4, PDB code: 3ODU 2.5 A ˚), we constructed three-dimensional models. The main aim of this study was to provide
relevant information on binding sites of these receptors. Molecular dynamics simulation was done to refine the homology
models and PROCHECK results indicated that the models were reasonable. Here, binding poses were checked with some
established inhibitors of high pharmaceutical importance against the modeled receptors. Analysis of interaction modes
gave an integrated interpretation with detailed structural information. The binding poses confirmed that the acidic residues
Glu291 (CCR2) and Glu283 (CCR5) are important, and we also found some additional residues. Comparisons of binding sites
of CCR2/CCR5 were done sequentially and also by docking a potent dual antagonist. Our results can be a starting point for
further structure-based drug design.
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Introduction
Chemokines are small (8–10 kDa) water-soluble proteins
consisting of 340–380 amino acid residues, which play key roles
in immuno-modulation and host defense. They selectively recruit
monocytes, neutrophils, and lymphocytes to sites of vascular injury
and inflammation [1–3]. Different chemokines produce various
leukocyte responses depending on the complementary nature of
their chemokine receptors [4,5]. The basic feature of inflammation
is the tissue recruitment of leukocytes, which is mediated mainly by
chemokines (chemotactic cytokines) via their receptors. The
chemokine super family can be categorized into four groups
(CC, CXC, CX3C, and C), according to the number and spacing
of conserved cysteines in the amino acid sequence [6–9]. Apart
from their well-recognized role in leukocyte recruitment, some
chemokines and chemokine receptors play crucial roles in other
cellular functions such as activation, proliferation, and differenti-
ation [6–9]. Specific family members are also involved in viral
entry and angiogenesis [9]. It was also reported that, a subset of
chemokine receptors plays a non-redundant role in infectious
diseases, as demonstrated by resistance to human immunodefi-
ciency virus/acquired immunodeficiency syndrome (HIV/AIDS)
in people homozygous for CCR5 D 32 (a loss of function mutation)
[10–14].
Because of their diverse range of important functions,
chemokines have been targeted as potential points of pharmaceu-
tical intervention for diseases as diverse as asthma, rheumatoid
arthritis, multiple sclerosis, solid organ transplantation, athero-
sclerosis, cancer, and HIV infection [9]. Since these chemokine
receptors are G protein-coupled receptors and targeted for diverse
diseases, many pharmaceutical and biotechnology companies have
devoted enormous time, effort, and expense in developing potent
small-molecule chemokine antagonists [15,16]. Accordingly, use of
two such antagonists, Maraviroc (a CCR5 antagonist) for the
treatment of HIV/AIDS [17] and Plerixafor (a CXCR4
antagonist) used in combination with granulocyte-colony stimu-
lating factor (G-CSF) to mobilize hematopoietic stem cells to the
peripheral blood for collection and subsequent autologous
transplantation in patients with non-Hodgkin’s lymphoma and
multiple myeloma have been approved by the United States Food
and Drug Administration (FDA) [18].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32864But, for chronic inflammatory diseases, clinical trials with
antagonists of a single chemokine receptor (e.g., CCR1, CCR2, or
CCR5) have not proved successful [15,16], which has been a
major setback. Considering the difficulty of pathogenesis of these
diseases and the potential for functional redundancy of chemokine
receptors, targeting a single receptor may not be adequate for
efficacy for these chronic conditions. CCR2 and CCR5 are two
CC chemokine receptors that are important players in the
trafficking of monocytes/macrophages and in the functions of
other cell types relevant to disease pathogenesis [19,20]. So,
structural information of CCR2 and CCR5 can be useful and
essential for providing insights about targeting these receptors.
Two recent studies have reported the use of dual antagonists
targeting both CCR2 and CCR5 [21,22].
Computational modeling has become an essential tool in
guiding and enabling rational decisions with respect to hypothe-
sis-driven biological research. In the absence of an experimentally
determined structure, homology modeling can provide a rational
alternative to a reasonable 3D structure. Knowledge of the 3D
structure of these receptors is important for understanding the
underlying molecular mechanisms of diseases caused by muta-
tions. Also, 3D structures will provide an opportunity for structure-
based drug design of small molecules acting as potent antagonist
and, provides the opportunity for site-directed mutagenesis studies.
The aim of this study was to provide adequate information
regarding the binding site of CCR2 and CCR5 receptors. We used
various computational techniques such as homology modeling,
docking, and molecular dynamic simulations (MDS). Homology
modeling of CCR2 and CCR5 was done using the crystal
structure of CCXR4 as the template [23]. These homology models
were further refined using MDS, and docking was done for the
potent antagonists of CCR2 and CCR5 against the modeled
receptor structure. Also, active sites of CCR2 and CCR5 were
compared. A potent dual antagonist was docked into the active site
(CCR2/CCR5) and results were analyzed.
Materials and Methods
Sequence analysis of CCR2 and CCR5
The human sequences of CCR2 and CCR5 were retrieved from
the Uniprot KB/TrEMBL database (accession numbers P41597
and P51681). In order to identify an adequate template for
modeling of CCR2 and CCR5 chemokine receptors, the Basic
local alignment search tool for protein (BLAST) algorithm [24,25]
was carried out against the protein data bank [26]. After the
search, the alignment between the template and the target
sequences (CCR2 and CCR5) was performed using ClustalW
2.0 [27] with default parameters.
Comparative modeling of CCR2 and CCR5
A number of homologous structures were identified as templates
in the protein data bank. Among the available templates from
search, CXCR4 (protein data base code: 3ODU; resolution-2.5 A ˚)
[23] was found as top template, and subsequently comparative
modeling was done. With the given identified hit as template
structure, sequence alignments for query sequences (P41597 and
P51681) were carried out. The structures of both CCR2 and
CCR5 were generated using the Modeller9v4 program [28–30].
Modeller9v4 calculates a model composed of non-hydrogen
atoms, based on the alignment of the sequence to be modeled
with known related structures. A 3D model was obtained by
optimization of a molecular probability density function (PDF)
using a variable target function procedure in Cartesian space that
employs methods of conjugate gradients and molecular dynamics
with simulated annealing. One hundred 3D models were
generated for both CCR2 and CCR5, and the models with lower
molecular probability density function (Molpdf) score and lower
root mean square deviation (RMSD) value were selected for
further computational study. The selected CCR2 and CCR5
models were refined by molecular dynamic simulations and were
further validated using PROCHECK [31], ERRAT [32] and
ProSA (https://prosa.services.came.sbg.ac.at/prosa.php) analyses.
Molecular dynamics simulation (MDS)
MDS were performed to produce good starting structures for
docking study. At this stage, the minimum energy conformers of
CCR2 and CCR5 obtained from comparative modeling were used
as the starting structures for MD simulation. Protein and water
molecules were used as the components for the simulation.
To remove bad contacts of the modeled receptors and to
achieve good starting structures, the models (CCR2 and CCR5)
were refined using MDS of 5000 ps with the GROMACS package
using the GROMOS96 force field [33]. The initial structures
(CCR2 and CCR5) were placed in a 0.9 nm cubic box. The
extracellular regions of the receptor are hydrophilic in nature,
whereas the transmembrane domains are hydrophobic in nature.
As the TM’s are hydrophobic, care was taken that no water
molecules are present in those regions. The SPC water model
[34,35] was used to create the aqueous environment for both
models. Periodic boundary conditions were applied and the
systems were further neutralized by adding appropriate counter
ions (Na+ and Cl2). The system was then subjected to 500 steps of
energy minimization using a steepest descent algorithm [36] to
reduce the effect of unfavorable interactions produced by
generation of solvents and ions.
The models (CCR2 and CCR5) were further subjected to full
MDS for a period of 5000 ps without restraints. During this phase,
(NVT) and (NPT) ensembles were used. The Berendsen coupling
scheme was used with both ensembles. All bond lengths were
constrained using the LINCS algorithm [37]. The SETTLE
algorithm was used to constrain the geometry of water molecules
[38].
Binding site construction and docking analysis
The Autodock 4.0 program was used for docking calculations.
Autodock uses the Lamarckian genetic algorithm (LGA) and is
regarded as the best method in terms of its ability to deduce the
lowest energy structure and the accuracy of its structure
predictions [39]. Hydrogen atoms and the active torsions of
ligands were assigned using Autodock tools (ADT). The binding
site for the receptor structures (CCR2 and CCR5) was created
according to previously published results. With this prior
knowledge, the binding site was created within 5 A ˚. An autogrid
was further employed to generate grid maps around the active site
with 60660660 points and grid spacing set to 0.375 A ˚. Docking
parameters modified from the defaults were the number of
individuals in the population (set to 150), maximum number of
energy evaluations (set to 2,500,000), maximum number of
generations (set to 27,000), and number of GA runs (set to 20).
The final conformations were clustered and ranked according to
the Autodock scoring function as well as with the knowledge of
crucial residues determined by mutational studies and experimen-
tal analysis. In this study, the binding mode of some of the potent
inhibitors reported for CCR2 and CCR5 were determined and
analyzed (Figure 1).
In Silico Analysis of CCR2 and CCR5
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Sequence analysis of CCR2 and CCR5
A BLAST search revealed 35% sequence identities between
template (3ODU) and query sequences (CCR2 and CCR5), and a
60% identity between the active sites of template and query. The
sequences showed a high level of homology between the target and
template sequences and were better than that of the traditional
bovine rhodopsin and the more recent b2-adrenergic receptor
templates. The obvious reason for this is the template sequences
are from the close homologue (CXCR4). The more significant step
in the modeling procedure is to obtain an acceptable alignment of
the target with the template sequences. This was performed and
the alignment obtained using ClustalW 2.0 is shown in Figure 2.
The expectation value (E-value) represents a number of different
alignments with scores equivalent to or better than the scores that
are expected to occur in a random database search. Generally, a
lower E-value indicates that alignment is real and does not occur
by chance. The E-value for CCR2 and CCR5 was 2e-33 and 1e-
33, respectively.
Homology modeling
The A-chain of CXCR4 was used to develop the 3D models
and a modeler program was used to derive 3D-models of CCR2
and CCR5. In the models, the seven-transmembrane (TM) helixes
are correctly transformed according to that of the template
(3ODU) structure. One hundred models were developed for both
CCR2 and CCR5. Finally, a model (CCR2 and CCR5) with a
lower MolPdf value and the one that displayed a lesser RMSD was
selected for further computational analysis. More than 90% of the
members of the GPCR super family have conserved disulfide
bridges. In CCR2, disulfide bridges were created between Cys32–
Cys277 and Cys113–Cys190. In CCR5, the disulfide bridges were
maintained between Cys20–Cys269 and Cys101–Cys178. The
selected models were further validated stereo-chemically using
additional parameters such as PROCHECK [31]. The Rama-
chandran plot for model before refinement by MDS is shown in
the materials S1 and S2.
Molecular dynamics simulation
The models (CCR2 and CCR5) selected from modeler was
further refined by MDS, to improve and access the stability of the
model. We also implemented MDS to find the energetically
favorable structure for further docking analysis. Our analysis based
on the trajectory revealed that the potential energy of the model
(CCR2) decreased from 21.281e+06 KJ/mol to 21.286e+06 KJ/
mol. However, in the case of CCR5, a decrease in the potential
energy was more and it varied from 21.257e+06 KJ/mol to
21.261e+06 KJ/mol. Most of the structures are around the area
of 21.283e+06 KJ/mol and 21.259e+06 KJ/mol for CCR2 and
CCR5, respectively. These data indicate the energetic stability of
CCR2 and CCR5. The potential energy plot for CCR2 and
CCR5 is shown in Figure 3.
The models were also evaluated on the basis of structural
stability using the RMSD calculated by variation in structure with
respect to time. The first 1000 ps were considered as the period of
equilibration. For CCR2, there was a gradual rise until 0.35 nm
followed by a plateau (Figure 4a). For CCR5, a gradual rise was
observed until 0.45 nm and a plateau was observed throughout
the rest of the period (Figure 4b). These results also indicate the
structural stability of the models.
One of the lowest potential energy conformations of CCR2 and
CCR5 was selected and refined by simple minimization. The
selected models were further validated stereo-chemically using
PROCHECK [31] and ERRAT [32] plots. The statistical
parameters obtained for both the CCR2 and CCR5 models are
summarized in Table 1. Ramachandran plot for the CCR2 model
showed that most of the residues are in mostly favored and
additionally allowed region. Similarly, in case of CCR5, the
residues are in mostly favored additionally allowed and generously
allowed regions. MDS shifted only one residue of CCR2 (Ser156)
and CCR5 (Leu159) into the disallowed region. Analyses of both
the structures for particular residues indicated that none of the
residues are part of the active site. The Ramachandran plot for the
CCR2 and CCR5 models is shown in Figure 5.
ERRAT plot analysis indicated that the overall quality factor for
non-bonded atomic interactions between atom types. Models with
Figure 1. Chemical structures of studied compounds using molecular docking. CCR2 (Compound 2, 14, RS-504393 and Teijin), CCR5
(Maraviroc, SCH351125, TAK779 and Vicriviroc) and dual inhibitors (Compound 19).
doi:10.1371/journal.pone.0032864.g001
In Silico Analysis of CCR2 and CCR5
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Presently, the ERRAT score was found to be 89.92 for CCR2 and
90.78 for CCR5 and it is better than those models which were
obtained before MDS which indicating the quality of the
generated models. In addition to this, we also validated our
models using Prosa which evaluates the energy of the structure
using distance pair potential. Residues with negative Prosa score
confirm the reliability of the model. The Prosa energy score for the
template was found to be -2.34 and for the models it was found to
be better (CCR2: Before MD - 2.54, After MD - 2.80; CCR5:
Before MD - 2.80, After MD - 2.93). The Prosa energy plot is
shown in materials S3.
Overall, our results indicate the selected models are satisfactory.
The quality of the model was evident by ERRAT score as well as
the Prosa energy scores. On the other hand, results PROCHECK
showed slightly worsened values of selected models. However,
from the results we can conclude that almost all the residues are in
most favored and additionally allowed regions except a single
residue in both CCR2 and CCR5. Both the residues do not have
prime importance and most importantly, the active site residues
Figure 2. Sequence alignment of CCR2 (UniProtKB: P41597) and CCR5 (UniProtKB: P51681) with the CXCR4 (PDB ID; 3ODU) as
template. Star indicates identical amino acids; colon indicates similar amino acids and single dot designate almost similar amino acid.
doi:10.1371/journal.pone.0032864.g002
Figure 3. Potential energy plot of MD simulation. (a) CCR2 and (b) CCR5 plot shows the variation in potential energy throughout the system for
a period of 5 ns. Time is on the X-axis and the potential energy is on the Y-axis.
doi:10.1371/journal.pone.0032864.g003
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slight drift in the RMSD of the protein models after MDS is quite
common and it is evident in the literature. After a period of
equilibration, the structures were found to be stable throughout
the simulation (Figure 4a and Figure 4b). These refined models of
CCR2 and CCR5 were further used for docking analyses and are
shown in materials S4 and S5, respectively.
Prediction of interaction between potent CCR2
antagonists and CCR2 receptor
Binding site of CCR2. Receptor homology modeling
suggests that the antagonists bind in an extended pocket
bounded by TM2, TM3, TM5, TM6, and TM7. It has been
proposed from mutagenesis studies that Glu291 from TM7 is an
Figure 4. Graphical representation of root mean square deviation (RMSD) plot. RMSD for (a) CCR2 and (b) CCR5 Ca from the initial
structures throughout the simulation of 5 ns as function of time.
doi:10.1371/journal.pone.0032864.g004
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knowledge of these previously published results, the binding
pocket was determined. The binding pocket was composed mainly
of residues Phe35, Val37, Leu45, Tyr49, Trp98, Ser101, Ala102,
Tyr120, His121, Tyr124, Phe125, Ala171, Ser172, Pro174,
Gly175, Val189, Phe194, Arg206, Asn207, Trp256, Tyr259,
Gln288, Glu291, Thr292, and Met295, similar to previous studies
[4,40]. The residues that guided docking are shown in Figure 6a.
As the proposed binding pocket was similar, some of the potent
CCR2 antagonists were docked into the binding site.
Docking studies of CCR2 antagonists. A wide variety of
structurally diverse small molecule antagonists have been reported
in the literature. However, only few of them are reported using a
combined in silico analysis and mutagenesis studies to propose the
binding site of CCR2 [4,40]. In this study, we used potent
antagonists such as (R)-3-aminopyrrolidine (Teijin lead),
cyclohexyl and pyridyl derivatives, and RS-504393. Binding
energies of all docked CCR2 inhibitors are given in materials S6.
Docking studies of (R)-3-aminopyrrolidine (Teijin
lead). A series of CCR2 antagonists have been reported [41].
The reported compounds were derivatives of the Teijin lead. The
highly active compound of the (R)-3-aminopyrrolidine
(IC50=3.2 nM) series was docked into the proposed binding
site. Different conformations were generated and the
conformations with the top cluster were selected. The ligand
established crucial interactions with important residues in the
binding site. The basic nitrogen in the pyrrolidine ring formed an
electrostatic interaction (i.e., salt bridge) with crucial and
conserved Glu291. The distance between the glutamic acid
residue and the basic nitrogen was 3.95 A ˚. The ligand also
formed hydrogen bond interactions with Tyr120 and His121. In
addition to some of the hydrogen bonds, hydrophobic interactions
were also observed between the ligand and the receptor. The 2,4-
di-phenyl ring lay in the pocket lined by residues Tyr49, Trp98,
and Ser101. Similarly, the trifluoro methyl group lay inside the
cavity occupied by residues such as Phe125, Pro174, and Arg206.
The binding mode of the ligand and its interaction with the
receptor structure is shown in Figure 7a.
Docking studies of RS-504393. RS-504393 has been
identified as a potent CCR2 antagonist [4]. The authors
reported a group of spiropiperidine derivatives as potent
Figure 5. Ramachandran plot for the models after MD simulations. (a) CCR2 and (b) CCR5 models are shown. The different color coding
indicates most favored (red), generously allowed (dark yellow), additionally allowed (light yellow), and disallowed (white) regions.
doi:10.1371/journal.pone.0032864.g005
Table 1. Validation results of CCR2/CCR5 homology model before and after MDS.
PROCHECK
Model ERRAT %
Core % Additionally allowed % Generously allowed % Disallowed %
CCR2 (Before MD) 92.9 7.1 0 0 87.04
CCR2 (After MD) 84.1 14.7 0.8 0.4 89.92
CCR5 (Before MD) 92.8 6.8 0.4 0 88.41
CCR5 (After MD) 84.8 13.7 1.1 0.4 90.78
doi:10.1371/journal.pone.0032864.t001
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proposed as the most active one; we used this derivative
(IC50=89 nM) for in silico docking simulations. The authors also
found that the basic nitrogen present in the spiropiperidine
compounds may be the interaction partner for Glu291. With this
knowledge, the docking modes were analyzed and the binding
pose was selected. The basic nitrogen in the spiropiperidine ring
formed a salt bridge contact with Glu291 at a distance of 5.3 A ˚.
Hydrogen bonding interactions were also observed between the
ligand and the receptor. The other nitrogen of this spiropiperidine
ring hydrogen bonded with Tyr49. The oxygen atom present in
this ring also forms a hydrogen bond with Tyr120. Moreover
additional hydrophobic interactions were observed between the
ligand and the active site residues. The binding pose of the ligand
and its interaction with the receptor structure is shown in
Figure 7b.
Docking studies of cyclohexyl and pyridyl
derivatives. Cherny et al. proposed a series of cyclohexyl and
pyridyl derivatives as CCR2 antagonists [42]. They compared
cyclohexane and piperidine derivatives and concluded that
addition of the piperidine nitrogen alone can significantly
enhance CCR2 affinity. Presently, we used one of the pyridyl
(compound 14) derivatives (IC50=6.3 nM) and a cyclohexyl
(compound 2) derivative (IC50=1180 nM) for docking analyses.
Two Hydrogen bond interactions were observed between the
receptor and the pyridyl derivative. The amide nitrogen of the
pyridyl derivative, which is positioned close to the phenyl ring,
interacts with the crucial Glu291. In addition, the nitrogen present
in the piperidine ring interacts with Thr287 through hydrogen
bond. The S-methyl group lies inside the pocket lined by residues
Trp98, Ala101, Ser102, Val189, and Cys190. In case of the
cyclohexyl derivative, the amide nitrogen interacts with Tyr120
and Glu291. Additional hydrophobic interactions were also
observed between ligand and the receptor, similar to that of the
pyridyl derivative. The binding pose of ligand and its interaction
with the receptor structure is shown in Figure 7c and 7d.
Prediction of interaction between potent CCR5
antagonists and CCR5 receptor
Binding site of CCR5. The binding pocket for CCR5
inhibitors was determined based on the previously published
mutagenesis studies [43–47]. The binding pocket is located at
extracellular region and is partly covered by the extracellular loop
2 (ECL2). It mainly composed of conserved residues Tyr37 (TM1),
Trp86 (TM2), Tyr108 (TM3), Phe109 (TM3), Phe112 (TM3),
Gln194 (TM5), Ile198 (TM5), Trp248 (TM6), Tyr251 (TM6),
Gln280 (TM7), Glu283 (TM7), and Met287 (TM7). The binding
pocket comprising residues along with TM regions are shown in
Figure 6b. A literature review has suggested that the crucial acidic
residue (Glu283) in TM7 of the binding pocket could establish
ionic interactions with tertiary/quaternary nitrogen of inhibitors
(Maraviroc, SCH-C, TAK779, and Vicriviroc).
Docking studies of CCR5 antagonists. A wide variety of
potent and highly active CCR5 antagonists were used in docking
studies. Potent CCR5 antagonists used in docking simulation
included Maraviroc, SCH-C, TAK779, and Vicriviroc. The
mutational data for all these compounds were previously
reported and were collectively used to determine the binding
pocket of CCR5. Binding energies of all docked CCR5 inhibitors
are given in materials S6.
Docking study with Maraviroc. Maraviroc (IC50=
0.56 nM) was first identified as potent CCR5 antagonists by
Pfizer pharmaceutical [48]. FDA has licensed this compound as a
Figure 6. Top views of putative binding pockets after MD simulation for docking analyses. (a) CCR2 transmembrane (TM) helices are
shown in light green, whereas, constructed binding pocket residues were shown in smudge green sticks. All the TM regions are labeled by blue color
on the top of helices. The binding pocket is also represented as transparent molecular surfaces. (b) CCR5 TM helices are shown in light brown color,
whereas constructed binding pocket residues were shown in green sticks. Figure generated using Pymol program (http://www.pymol.org).
doi:10.1371/journal.pone.0032864.g006
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commercially available since August 2007 for HIV-1/AIDS
chemotherapy. In this study, Maraviroc had established crucial
interactions with the binding pocket of CCR5. Salt bridge contact
Figure 7. Binding modes of CCR2 inhibitors. TM helices are shown in pale green color, whereas constructed binding pocket residues were
shown in cyan sticks. All the TM’s are labeled by blue color on the top of helices. Docked ligands were shown in magenta color. (a) Docking model of
Teijin shows key salt bridge interaction between pyrrolidine nitrogen and Glu291 by magenta dotted lines. Hydrogen bonding interactions are also
observed with Tyr120 and His121. (b) RS-50323 shows salt bridge interaction between the linker nitrogen of the ligand and Glu291 which is indicated
by magenta dotted lines. (c) Pyridyl derivative show crucial interaction between the hydrogen atom of the nitrogen and Glu291 which is indicated by
magenta dotted lines. Hydrogen bonding interaction is also observed with Thr287. (d) Docking model of cyclohexyl derivatives identified crucial
interaction between the hydrogen atom of nitrogen and Glu291 (magenta dotted lines). In addition, the same atom also hydrogen bonded with
Tyr120.
doi:10.1371/journal.pone.0032864.g007
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CCR5 at a distance of 4.55 A ˚. Tyr37 makes a hydrogen bond with
triazole ‘N’ of Maraviroc (1.88 A ˚), and another hydrogen bond
interaction was observed with carboxamide ‘O’ of Maraviroc
against Tyr108 (2.17 A ˚). The isopropyl group of the triazine ring is
situated deep inside the pocket formed by the hydrophobic
residues Trp86, Tyr108, and Met287. The phenyl ring of the
ligand docks into a cavity formed by residues Tyr108, Phe109, and
Ile198. The para-difluoro-cyclohexane ring of ligand docks into a
hydrophobic pocket determined by Phe112, Phe113, Ile198,
Tyr251, and Leu255. The base of the pocket is formed by the
highly hydrophobic residues (Phe112 and Phe113). A central fused
bi-cyclic ring interacts hydrophobically with the Trp86, Tyr108,
and Thr167 residues. The docked pose of Maraviroc within the
CCR5 pocket is shown in Figure 8a.
Docking study with SCH-C. SCH-C (SCH-351125) was
identified as a potent CCR5 antagonist by Schering-Plough
Research institute in 2001 [49] with CCR5 activity at 0.69 nM.
To gain insight into how SCH-C interacts with CCR5, a
molecular docking study was performed. SCH-C interacts with
CCR5 through hydrogen bond and hydrophobic interactions. Salt
bridge contact was observed between the tertiary ‘N’ of SCH-C
and CCR5 Glu283 at a distance of 4.67 A ˚. It seems that the salt
bridge contact acts like an anchor to hold the ligand in the
receptor cavity. Hydrogen bond interaction was observed between
the piperidine-N-oxide of SCH-C and the Tyr37 of CCR5.
Moreover, this piperidine-N-oxide seems to interact through the p
- p stacking interactions with Trp86 of CCR5. Another p - p
stacking interaction was observed with terminal 4-Br-phenyl of
SCH-C and Phe112. The 4-bromophenyl moiety of ligand docks
deeply in the receptor pocket lined by residues Phe112, Ile198,
Trp248, Tyr251, Asn252, and Leu255. SCH-C interacts through
hydrophobic interactions with the receptor pocket lined by
residues Tyr37, Trp86, Tyr89, Tyr108, Phe109, Phe112,
Gly163, Gln194, Ile198, Trp248, Tyr251, Asn252, Leu255, and
Glu283. The docked pose of SCH-C with the CCR5 binding site
is shown in Figure 8b.
Docking study with TAK779. TAK779 was discovered by
Takeda pharmaceuticals as a potent anti HIV-1 agent targeting
CCR5. Biological assays revealed CCR5’s antagonism potency
against CHO (1.4 nM) [50]. TAK779 interacts through
hydrophobic interactions. Strong salt bridge contact between
quaternary ‘N’ of TAK779 and Glu283 of CCR5 is observed at a
distance of 3.95 A ˚. Hydrogen bond interaction was formed
between the central amide carbonyl of TAK779 and Thr167.
The docked pose revealed that TAK779 is oriented as a L-shape
inside the binding pocket. A T-shaped interaction between the
Tyr251 and the fused ring of TAK779 is present. A 4-
methylphenyl substituent on the fused ring docks into a cavity
formed by Phe112, Phe113, Ile198, Tyr251, Asn252, and Leu255.
The base of this pocket is formed by the highly hydrophobic
residues such as Phe112 and Phe113. TAK779 docks in the
binding pocket lined by residues Tyr37, Trp86, Tyr89, Phe112,
Phe113, Gly163, Thr167, Ile198, Gln194, Tyr251, Asn252,
Leu255, Gln280, and Glu283. The docked pose for TAK779
along with residues is shown in Figure 8c.
Docking study of Vicriviroc. Discovery and charac-
terization of Vicriviroc as potent CCR5 antagonists was done by
Strizki et al. [51]. These authors reported Vicriviroc to be 2–40
folds more potent that SCH-C. Presently, a docking study was
performed to discern the molecular mechanism of interaction
between the ligand and the protein. The docked pose revealed that
the ligand-protein interaction is mainly hydrophobic. The tertiary
‘N’ of Vicriviroc makes salt bridge contact with Glu283 at a
distance of 4.87 A ˚. The hydrophobic 4-Trifluoro-phenyl part of
Vicriviroc docks deeply into a cavity formed by residues Phe112,
Ile198, Trp248, Tyr251, Asn252, and Leu255. Another observed
hydrophobic interaction is between the pyrimidine ring of the
ligand and Trp86, mainly a p - p stacking interaction. Vicriviroc
docks into a receptor pocket lined by amino acid residues Tyr37,
Trp86, Tyr89, Tyr108, Phe109, Phe112, Ala159, Thr167, Ile198,
Gln194, Trp248, Tyr251, Asn252, Leu255, and Glu283
(Figure 8d).
Comparative analysis of CCR2 and CCR5
We compared the sequences of CCR2 and CCR5, and found
66% sequence identity. They also share 82% identity in their
active sites. From the alignment (materials S7) we found that most
of the residues are conserved. Since dual targeting of CCR2 and
CCR5 is of prime importance in current drug discovery, we
moved our focus towards the binding site of these receptors. We
superimposed the binding sites of both receptors and analyzed the
variation of residual information. Our analysis revealed that
almost all the residues are identical except three residues. The
varying residues in CCR2/CCR5 are Ser101/Tyr89, His121/
Phe109, and Arg206/Ile198; these makes difference in their
electrostatic properties. More specifically, Ser101 is hydrophilic
and Tyr89 is hydrophobic in nature. Similarly, His121 and
Arg206 are hydrophilic, whereas Phe109 and Ile198 are
hydrophobic in nature. While designing dual inhibitors one may
consider this variation of active sites residues for potent inhibition
of dual targets. Mutational studies on these residues could also be
effective. The superimposed binding site of CCR2/CCR5 is
shown in materials S8.
Docking study of dual antagonists into the binding site
of CCR2 and CCR5
A series of antagonists targeting both CCR2 and CCR5 has
been proposed [21]. Among the series of potent inhibitors,
compound 19 was shown to be more potent and inhibited both
CCR2 (3 nM) and CCR5 (5.3 nM). To gain crucial information
about interaction between this compound and the receptor (CCR2
and CCR5), compound 19 was docked into the binding site of
these receptors. The binding mode of this compound inside the
receptor active sites was analyzed. The tertiary nitrogen of the
ligand forms a salt bridge (i.e. electrostatic interaction) contact
with the crucial acidic residue (CCR2-Glu291; CCR5-Glu283).
The distance between the tertiary nitrogen of the ligand and the
acidic residue is 3.97 A ˚ for CCR2 and 4.48 A ˚ for CCR5. These
interactions are likely necessary for high affinity binding.
Structural activity relationship study of derivatives of this
compound showed that replacement of 4-[3-(trifluoromethyl)phe-
nyl]piperidine by 1-[3-(trifluoromethyl)phenyl]piperazine enhanc-
es inhibitory activity 52-fold against CCR2 [21]. The tertiary ‘N’
present in the piperazine ring markedly influences activity,
explaining the importance of the tertiary ‘N’ in the present study.
Our study implies that interaction occurs through the salt bridge
contact with acidic residues. We also found that the trifluor-
omethyl substitution close to the tertiary nitrogen make them able
to interact with Arg206/Ile198 of CCR2/CCR5. The binding
mode of compound 19 inside the binding site of CCR2 and CCR5
is shown in Figure 9a and 9b, respectively. The binding poses of
this dual antagonist indicate that filling the hydrophobic cavities of
both CCR2 and CCR5 would be necessary to develop more
potent dual antagonists. Binding energy of dual antagonist is given
in materials S6.
In Silico Analysis of CCR2 and CCR5
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32864Binding patterns of docked molecules against CCR2 and
CCR5 models
Our binding pattern of drug matches partially to that of
CXCR4 ligand (IT1t), and it overlaps with other GPCR ligands
such as, retinal (rhodopsin), carazolol (b2AR) and ZM241385
(A2AAR) (materials S9). Materials S9a was generated with the
alignment of 1U19 (rhodopsin), 2RH1 (b2AR), 3EML (A2AAR),
Teijin with CCR2 model and TAK779 with CCR5 model over
the template structure (CXCR4). Materials S9b was generated as
a hypothetical model of materials S9a. In our docked model,
Teijin (white carbon, materials S9a) was partially overlapped with
the native ligands IT1t (3ODU), and ZM241385 (3EML), and it
also bound in TM1, TM2, TM3, TM4 and TM7 as IT1t do. Also,
Teijin overlaps the binding site of CVX15 peptide (native peptide
ligand of 3OE0) at the TM3, TM4 and TM5 with close contacts of
Tyr120, His121, Pro174 and Arg206. It was also observed an
essential salt bridge interaction with the Glu291 of CCR2.
TAK779 [green carbon, materials S9a] bound to CCR5 model
in a L-shaped orientation which cover the binding sites of GPCRs
ligands such as retinal, carazolol, ZM241385, IT1t and CVX15.
Quaternary ammonium nitrogen of TAK779 interacts with the
Glu283 of CCR5 through salt bridge contact. However, TAK779
binds in a pocket formed by residues of TM1, TM2, TM3, TM5,
TM6 and TM7. Docked pose of TAK779 indicates that, it
Figure 8. Binding modes of CCR5 inhibitors. TM helices are shown in light brown color, whereas constructed binding pocket residues were
shown in green sticks. All the TM’s are labeled by blue color on the top of helices. Docked ligands were shown in yellow color. (a) Docked pose of
Maraviroc in CCR5, the key salt bridge interaction with Glu283 is shown by magenta dotted line. Hydrogen bonds with Try37 and Tyr108 were shown
in blue dotted lines. (b) Docking model of SCH-C show a key salt bridge interaction with Glu283 and represented by magenta dotted line. Hydrogen
bond with Try37 is shown as blue dotted lines. Pyridine-N-Oxide ring of ligand interacts through strong aromatic p-stacking interaction with the
Trp86 of CCR5. (c) TAK779 in CCR5 shows salt bridge interaction with Glu283 which is designated by magenta dotted line. Hydrogen bonds with
Try37 and Thr167 are shown in blue dotted lines. Phenyl group of TAK779 docked deeply inside the cavity formed by Ile198, Tyr251, Asn252 and
Leu255. (d) Docking model of Vicriviroc shows salt bridge interaction with Glu283 which is indicated by magenta dotted line. Pyrimidine ring of
ligand interacts strongly via p-stacking interaction with Trp86. Tri-fluoro-phenyl of ligand is docked deeply into the cavity formed by Phe112, Ile198,
Trp248, Tyr251, Asn252 and Leu255 residues.
doi:10.1371/journal.pone.0032864.g008
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e32864penetrates deep into the pocket formed by TM5, TM6 and TM7
where retinal binds with bovine rhodopsin (1U19). Furthermore,
the docked models of other potent antagonists used in this study
expressed the similar binding pattern of above mentioned ligand
molecules (Teijin and TAK779). Our docked poses overlap the
binding sites of these co-crystal ligands and may hinder the
activation of receptors. Multiple ligand sites in GPCR shows that
the plasticity of binding site. Our docking models of different
inhibitors for CCR2 and CCR5 explain the phenomenon of
binding site plasticity.
Discussion
CCR2 and CCR5 are two CC chemokine receptors that are
important players in the trafficking of monocytes/macrophages
and in the functions of other cell types relevant to disease
Figure 9. Docked models of dual inhibitor (compound 19). (a) Docking model of compound 19 in CCR2 is shown in transparent surface. Salt
bridge interaction of tertiary nitrogen with Glu291 is shown by dotted magenta lines, whereas hydrogen bond interaction of ligand-fluorine with
Arg206 is shown by dotted cyan line. Side chains of interacting residues of CCR2 are shown in cap stick (cyan color), while ligand is shown in cap-stick
with green color for carbon. (b) Binding mode of compound 19 in CCR5 cavity. Salt bridge interaction of tertiary nitrogen with Glu283 is shown by
dotted magenta lines, whereas hydrogen bond interaction of pyridine nitrogen with Tyr108 is shown by dotted cyan line. Side chains of interacting
residues of CCR5 are shown in cap stick (green color), while ligand is shown in cap-stick with cyan color for carbon. Trifluoromethyl group of ligand
was docked into the hydrophobic cavity.
doi:10.1371/journal.pone.0032864.g009
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PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e32864pathogenesis [19,20]. Clinical studies suggested that targeting just
a single receptor may not be adequate enough for efficacy.
Considering the importance of CCR2 and CCR5, the need for
developing dual target antagonists is of prime concern. Because of
the lack of structural information, targeting both CCR2 and
CCR5 receptors has been difficult. In the absence of structural
information, ligand-based approaches have proven to be especially
useful for G protein-coupled receptor (GPCR) [52]. However, in
the absence of X-ray structure, homology modeling could be an
important alternative and we implemented a combined ligand and
structure based analysis in this study.
Only a few studies have been reported concerning modeling of
the structure of CCR2 through a comparative modeling approach
[40,53–55]. All the reported homology models were developed
using the traditionally used bovine rhodopsin and the recently
reported b2-adrenergic receptors as templates. However, in the
case of CCR5, most of the reported models involved the use of the
traditional bovine rhodopsin structure [56–61]. We also studied
CCR2 and CCR5 using in silico methodologies [62,63] and both
these structures will be important for modelers as well as
experimentalists in the scientific community. With the availability
of the recently reported close homolog, CXCR4 [23], modeling of
CCR2 and CCR5 was performed.
One of the main advantages of CXCR4 structure over bovine
rhodopsin is that it has higher sequence identity as well as a larger
binding pocket. Kimura et al. explained the importance of
expansion of binding site for the models developed based on
bovine rhodopsin as the template [54]. From Kimura’s report it is
obvious that the binding site is small in case of bovine rhodopsin.
So, we estimated the binding pocket volume of recently reported
CXCR4 (1137 A ˚ 3) and b2-adrenergic (1145 A ˚ 3) receptor struc-
tures. It implies that the binding pockets are comparatively big.
Secondly, this template (CXCR4) is more closer with the sequence
identity of 35.4% with CCR2 and CCR5, which is quite higher
than bovine rhodopsin (23.3%), human b2AR (25.4%) and human
A2AAR (22.2%) receptor templates. Hence this higher identity
implies that the CXCR4 template suits better for modeling study.
The molecular docking study was carried out using the modeled
receptor structure. Some of the potent antagonists of CCR2 and
CCR5 were docked into the proposed binding sites. The binding
site of CCR2 [4,40] and CCR5 [43–48] were developed according
to previously proposed sites and were in good agreement with
already published results. We have identified residues in the
previous reports. In addition, we found some important residues
that are likely to be crucial in antagonism (CCR2 and CCR5).
Specifically, the obtained docking results for CCR2 antagonists
arewell correlated with theprevioussite directed mutagenesisstudy.
It also shows that hydrogen bond interaction is more important for
CCR2 antagonists and in accordance with previous reports [40,64].
Glu291 has been established as a crucial residue for the activity of
CCR2 antagonists through mutational studies, and our results
confirmed the importance of Glu291 in the active site which formed
salt bridge contacts with the antagonists [4,40]. Besides, our study
implies that Tyr120 and His121 may also be crucial for CCR2
antagonists, because Tyr120 and His121 form hydrogen bonds with
the ligand molecules. This result complements previous results
[40,64]. It was also observed that Y49, Trp98, Tyr120 and Glu291
forms tight aromatic cluster to accommodate Teijin into CCR2
cavity [65] which is in line with our results. In addition, the docking
studies indicated that Ser101, Ala102, Arg206, and Thr287 might
also be crucial through our docking studies and mutational studies
on these residues might be effective.
Similarly, docking result of CCR5 antagonists are well
correlated with that of the previous site directed mutagenesis
studies. Our docking study revealed that Glu283 is an important
residue in CCR5 antagonism, bolstering prior mutational studies
[43–47]. Docked poses of all the four inhibitors (MVC, SCH-C,
TAK-779, and Vicriviroc) indicated that ligands were bound
tightly in the active site. Additionally, we found some important
residues in active site, which might be crucial for CCR5
antagonism. Close interactions for all four antagonists (MVC,
SCH-C, TAK-779 and Vicriviroc) were observed with Tyr89
(TM2), Gly163 (TM4), Thr167 (TM4), Asn252 (TM6), and
Leu255 (TM6). Tyr37, Trp86, Tyr108, Ile198, Glu283 are
important in CCR5 antagonism [43–47,61,66]. Interactions were
mainly hydrophilic and hydrophobic in origin. Further mutational
studies on these residues might be effective to locate the
contribution of these residues towards CCR5 antagonism. Recent
report on TAK779 modeling by Peterlini et al., [67] showed that
positively charged quaternary ammonium nitrogen of TAK779
shows ionic interaction with the Glu283, which is in line with our
docked model.
Though our defined binding sites for both receptors are similar
to the previous results, there may be possibility of some limitations
with the current strategy of pose selection as we selected our
docked modes based on the top cluster, previous mutagenesis
results and binding energy of inhibitors. However, our docked
models identified the corresponding residues in TM1, TM2, TM3,
and TM7 with additional residues from the TM5 and TM6. Our
binding modes of the representative compounds Teijin and
TAK779 (CCR2 and CCR5) are in agreement with the previously
reported results in the literature [64]. Location and interactions of
identified residues are in line with the reported results in literature,
thus corroborates the reliability of our results.
We also compared the binding site residues of CCR2 and
CCR5. Most of the residues are similar. However, varying residues
in active sites of CCR2/CCR5 such as Ser101/Tyr89, His121/
Phe109, and Arg206/Ile198 were observed. Site-directed muta-
genesis studies on these residues can also be effective. We docked a
highly potent dual antagonist into the active site of CCR2 and
CCR5. The docked poses revealed that tertiary ‘N’ of the
piperazine ring makes salt bridge contact with the acidic residues
of CCR2/CCR5 and is important for antagonism. We further-
more found that trifluoromethyl substitution of ligand, which is
hydrophobic as well as electronegative in nature and which is
crucial for inhibiting both CCR2/CCR5. Docked poses revealed
that this group interacts with Arg206 of CCR2 and Ile198 of
CCR5. Introducing a bulky group to this dual antagonist would
increase binding affinities while substituting an electronegative
group would differentiate CCR2 and CCR5.
Supporting Information
Materials S1 Ramachandran plot of the CCR2 model
obtained before MDS. The different color coding indicates
most favored (red), generously allowed (dark yellow), additionally
allowed (light yellow), and disallowed (white) regions.
(TIF)
Materials S2 Ramachandran plot of the CCR5 model
obtained before MDS. The different color coding indicates
most favored (red), generously allowed (dark yellow), additionally
allowed (light yellow), and disallowed (white) regions.
(TIF)
Materials S3 ProSA energy plot for the CCR2 and CCR5
models before and after MD simulation.
(TIF)
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PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e32864Materials S4 Homology model of CCR2 obtained after
refinement by MDS. The TM domain regions are colored in
red and the loop regions are colored in green.
(TIF)
Materials S5 Homology model of CCR5 obtained after
refinement by MDS. The TM domain regions are colored in
red and the loop regions are colored in green.
(TIF)
Materials S6 Binding energy of all the docked inhibitors
by Autodock.
(XLSX)
Materials S7 Alignment obtained between the CCR2
and CCR5 sequences for sequence analysis. Identical
residues are marked as (*), similar regions are marked as (:).
(TIF)
Materials S8 Superposition of varying residues in the
active sites of CCR2 (cyan) and CCR5 (magenta). All the
TM’s are labeled by blue color on the top of helices.
(TIF)
Materials S9 Superposition of the GPCRs ligand. (a)
Binding sites of the GPCRs were mapped computationally. X-ray
structures of bovine rhodopsin (1U19), b2AR (2RH1), A2AAR
(3EML) were aligned over recent CXCR4 (3ODU) structure. As
well as the CCR2 and CCR5 model with docked Teijin and
TAK779 are aligned over 3ODU. Aligned ligands were shown;
retinal in yellow carbon, carazolol in brown carbon, ZM241385 in
magenta carbon, IT1t in cyan carbon, teijin in white carbon and
TAK779 in green carbon. (b) Hypothetical model of overlapping
binding sites were generated.
(TIF)
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